Abstract
Two doses of a recombinant Lyme disease vaccine (15 and 30 microg) were administered to children 2-5 years old (0-1-month schedule) and were well tolerated. Both doses were highly immunogenic with geometric mean titers 1 month after vaccination of 4366 and 9877 ELISA units (EU)/mL, respectively. Nearly all subjects had antibody levels of > or = 1400 EU/mL, suggesting protective tick titre for one tick season.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Antibodies, Bacterial / blood
-
Antigens, Surface / immunology
-
Bacterial Outer Membrane Proteins / immunology
-
Bacterial Vaccines
-
Borrelia burgdorferi Group / immunology
-
Child, Preschool
-
Humans
-
Lipoproteins*
-
Lyme Disease / immunology
-
Lyme Disease / microbiology
-
Lyme Disease / prevention & control*
-
Lyme Disease Vaccines / adverse effects*
-
Lyme Disease Vaccines / genetics
-
Lyme Disease Vaccines / immunology*
-
Vaccines, Synthetic / adverse effects
-
Vaccines, Synthetic / immunology
Substances
-
Antibodies, Bacterial
-
Antigens, Surface
-
Bacterial Outer Membrane Proteins
-
Bacterial Vaccines
-
Lipoproteins
-
Lyme Disease Vaccines
-
OspA protein
-
Vaccines, Synthetic